Where is legislation on biosimilars heading? How will this impact innovator biopharmaceutical and biotechnology companies? What is your position on the issue?
Please read my primer on the coming storm of biosimilars published in this month’s Pharmaceutical Executive. http://tinyurl.com/l64pe4
This piece provides a summary overview of the situation and communication strategies to help innovator companies prepare and communicate around this issue.
-- John Kouten